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Interleukin (IL) 10 is a recently discovered cytokine, origi-
nally isolated from T -helper 2 (Th2) cells, which inhibits 
cytokine production ofT-helper 1 (Thl) cells. Because Thl 
cells appear to be of importance during the contact hypersen-
sitivity reaction (CHS) we hypothesized that IL-l0 might 
modulate the outcome of CHS ill vivo. Intraperitoneal injec-
tion of murine recombinant IL-l0 (1000 ng) into naive mice 
24, 72, or 120 h before sensitization by epicutaneous applica-
tion of 2,4-dinitrofluorobenzene (ONFB) did not affect ear 
swelling when ears were challenged 5 d later. However, in-
traperitoneal injection of IL-l 0 into already sensitized mice 
24 h before challenge resulted in a significant suppression of 
the ear swelling response, suggesting that under the condi-
tions employed IL-l0 is able to block the effector phase, but 
not the induction phase of CHS ill vivo. The suppression 
could be reversed by the concurrent injection of an IL-l0 
antibody. Moreover, heat inactivation of native IL-10 re-
T he molecular mechanisms modulating the cellular in-teractions in contact allergic reactions are still poorly understood. However, there is strong evidence that the cytokine network and the interplay of accessory signals are part of this complex reaction. In particular, 
the involvement of cytokines offers promising aspects with regard 
to pharmacologic intervention and therapeutic options including 
the application of downregulating cytokines or cytokine antago-
nists. This is of major relevance because contact dermatitis is a quite 
frequently observed disease and can, particularly in the chronic 
stage, be a disabling disorder. 
There is good evidence that T-helper 1 (Thl) cells are critically 
involved in delayed-type hypersensitivity (DTH) and contact hy-
persensitivity (CHS) reactions [1). T-helper 2 (Th2) clones were 
shown to secrete interleukin(IL)-10, a cytokine that inhibits the 
production of interferon-y and IL-2 by Th 1 cells [2). It was subse-
quently shown that IL-I0 mediated its effects on T-cell function 
indirectly by inhibiting the antigen-presenting function of purified 
macrophages and monocytes, but not B cells [3 ,4). In addition, 
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suIted in loss of the inhibitory capacity. When mice were 
sensitized by subcutaneous injection of trinitrophenyl-cou-
pled spleen cells (OTH) instead of epicutaneous application 
of the hapten (CHS), intraperitoneally-injected IL-l0 sup-
pressed the effector phase, but also the induction phase of 
DTH. IL-10 did not inhibit the toxic ear-swelling response 
induced by topical application of two irritants tested (croton 
oil or benzalkonium chloride) . The capacity ofIL-10 to sup-
press the effector phase of CHS and OTH supports an impor-
tant role for this cytokine in the downregulation of type IV 
immune reactions ill vivo. The finding that IL-l 0 suppresses 
the induction ofOTH, bqt not of CHS, further suggests that 
CHS and OTH are related but distinct immune reactions. 
Key words: illterleukil1-10/contact hypersetlsitivity/delayed-
type hyper5etl5itivity /5 upp ressio 11. ] Illvest Dermatol 103:211-
216,1994 
IL-I0 acts as a mast cell [5] and T-cell growth factor [6] , and en-
hances B-cell viability and major histocompatibility complex class 
II expression on B cells [7]. IL-tO also suppresses the release by 
monocytes/macrophages of a variety of inflammatory mediators 
including IL-1, IL-6, IL-8, granulocyte/macrophage colony-stim-
ulating factor , granulocyte colony-stimulating factor, and tumor 
necrosis factor-a (TNF-a) [8,9]. These biologic abilities strongly 
suggest an important role for IL-10 in the downregulation of in-
flammatory and immune reactions, and support its possible clinical 
use as an immunosuppressor and antiinflammatory agent [9]. 
In view of the critical role that Thl cells play during CHS we 
investigated the role ofIL-10 during this reaction [1]. Our approach 
was to determine whether contact allergic reactions can be modu-
lated in vivo by injection ofIL-10 at the time of hapten sensitization 
or hapten challenge. Our results indicate that IL-10 can inhibit 
CHS i" vivo. 
MATERIALS AND METHODS 
Mice Balb/c and C3H/HeN mice between 8 and 12 weeks old were 
purchased from the Versuchstierzuchtanstalt, Hannover, Germany. 
Contact Hypersensitivity Mice were sensitized by painting 25 III of 
2,4-dinitro-fluorobenzene (DNFB; Sigma Corp., St. Louis, MO) solution 
(acetone: olive oi l, 4: 1) on the shaved abdomen on day 1 and day 2, as 
reported previously (10). On day 6 the left ear was challenged by applying 
20 III 0.3% DNFB, and the right ear was treated with acetone/olive oil 
alone. The degree of ear swelling was measured with a spring-loaded mi-
crometer (Mitutoyo, Japan) 24 h after challenge. Contact hypersensitivity 
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was determined as the amount of swelling of the hapten-challenged left ear 
compared to the thickness of the vehicle (acetone: olive oil)-treated right ear 
in sensitized anjmals and expressed in cm X 10- 3 (mean ± SO). Mice that 
were ear chaJlenged without prior sensitization served as negative controls. 
Each treatment group consisted of at least seven animals, and each experi-
ment was performed at least three times. 
Delayed Type Hypersensitivity Spleens were removed aseptically from 
naive donor mice (C3H/HeN) and teased apart in Hanks' balanced saline 
solution (HBSS). The suspensions were filtered through .nylon gauze to 
remove clumps and washed, red blood cells were lysed with Tns-NH.CI 
solution for 2 min, refiltered, and washed twice with HBSS. Cells were 
conjugated with trinitrophenyl by incubating them for 15 min at 37· C in 
10 mM recrystallized trinitrobenzene sulfonate in HBSS at pH 7.0. After 
incubation, the cells were washed three times to remove unconjugated hap-
ten. For sensitization,S X 10' trinitrophenyl-coupled spleen cells (TNP-
SC) were injected subcutaneously at two sites on the dorsal side of the micc. 
Challenge was performed after 7 d by injecting 2 X 107 TNP-SC (sus-
pended in 40 JlI) subcutaneously into the left footI:'ad. The respective cont~ol 
groups consisted of nuce that were either senslt1zed or chal lenged With 
uncouplcd spleen cel ls. Footpad swelling was measured with a spring-loaded 
micrometer 24 h after challenge. Oelayed type hypersensitivity was deter-
mined as the amount of swelling of the hapten-challenged left footpad 
compared to the thickness of the unneated right footpad in sensitized mice 
and expressed in cm X 10- 3 (mean ± SO). 
Irritant Dermatitis For induction of irritant dermatitis 20 Jll of 1 % cro-
ton oil (Serva, Heidelberg, Germany) dissolved in acetone were applied on 
the left ear [11 J. Ear swelling was measured 8 h after irritant application with 
a spring-loaded micrometer. Irritant reaction was determined as the amount 
of swelling of the irritant-treated left ear compared to the vehicle (acetone)-
treated right ear and expressed in cm X 10- 3 (mean ± SO). In some experi-
ments, a 5% solution of benzalkonium chloride (Sigma Corp.) in acetone 
was used to elicit irritant dermatitis. Application and measurement was 
performed identically as with croton oi l. 
IL-10 Treatment In Vivo Recombinant mouse IL-10 was expressed iu 
Eschericilia coli [12] and renatured and purified using ion exchange and hy-
drophobic interaction chromatography [13]. Mice were injected intra peri to-
neally with IL-10 diluted in sterile endotoxin-free saline in a total volume of 
"100 JlI at the times indicated in each cxperiment. Control mice were treated 
intraperitoneally with equal volumes of saline, which had no effect on the 
outcome of both the sensitization and challenge procedure. Likewise, intra-
peritoneal injection of IL-10 into naive mice did not affect ea.r thickness by 
itself. Heat inactivation ofIL-l0 was performed by heating at 90·C for 30 
min. Biologic activity of IL- l 0 was monitored using the thymocyte prolifer-
ation assay as described previously [14]. Neutralizing antibody cxperiments 
utilized a rat monoclonal immunoglobulin (lg)Gl antibody directed against 
murine IL-1 0 (UBI Company, Lake Placid, NY) or an isotype control (rat 
IgG l , The Binding Site Inc., Birmingham, U.K.) . 
Thymocyte Proliferation Assay Thymocytes obtained from 7-week-
old Balblc mice (1 X 105 per well) were cultured in flat-bottom 96-well 
plates with IL-l 0 (native or heat inactivated) at various concentrations in the 
presence of IL-2 (500 U/ml) and IL-4 (250 U/mJ) in 300 Jll of RPMl 
medium (Gibeo, Gaithersburg, MO) supplemented by L-glutamine 
(200 mM) , modified Eagle's medium (MEM) amino acids, MEM vitamins, 
sodium bicarbonate, penicillinelstreptomycin (Sigma), 5 X 10- 5 M 2-mer-
captoethanol, and 10% fetal bovine serum (Gibeo) for 4 d [14J. The wclls 
were then pulsed with 1 JlCi/well [3H]thymidinc and harvested 18 h later. 
Activity is expressed as cpm (mean of triplicates). 
Histology The ears were fixed in buffered formaldehyde, embedded in 
paraffin, sectioned, and stained with hematoxylineosin. 
Statistical Analysis The statistical significance of differences in the 
means for each experimental group was calculated with the Student t test. 
Mean differences were considered significant when p < 0.05. 
RESULTS 
Effect of IL-l0 on the Induction of CHS To evaluate the 
effect of IL-IO on the induction phase of CHS, groups of Balb/c 
mice were injected intraperitoneally with varying amounts of mur-
ine IL-I0 in 100 J.lI saline 24 h before epicutaneous sensitization 
with DNFB. In three independent experiments of this type, IL-10 
did not alter the outcome of CHS response upon ear challenge 6 d 
later (Fig 1A). Because suppression of the induction of CHS has 
been observed upon injection of supernatants obtained from UV-
irradiated murine keratinocytes 120 h before sensitization [10], a 
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Figure L Effect of IL-l0 on the induction phase of CHS. IL-l0 was in-
jected intra peritoneally at various concentrations into naive Balblc mice 
24 h before sensitization (AJ. IL-l0 (1000 ng) was injected intraperitone-
ally into Balblc mice at the·time points indicated before performance of 
sensitization (B). Ear challcllge was performed on the left ear 5 dafter 
sensi tization; 24 h later ear swelling was evaluated. CHS response is ex-
pressed as the difference (em X 10- 3, mean ± SO) of the thickness of the 
challenged left car minus the thickness of the vehicle-treated right ear. Ear 
thickness (mean ± SO) of the control was 21.2 ± 0.4 cm X 10- 3 (A) and 
20.6 ± 0.9 cm X 10-3 (B). Negative controls consist of unsensitized mice 
that wcre ear challenged only. Experiments were repeated at least three 
times; results show one representative experiment. n.s., not significantly 
different from positive control. 
kinetic analysis was performed by injecting 1000 ng IL-10 24, 72, 
or 120 h before hapten application. However, induction of CHS 
was not affected under any of these conditions (Fig 1B). 
Administration ofIL-l0 Results in Suppression of the Effec-
tor Phase of CHS DNFB-sensitized Balb/c mice received 1-
2000 ng ofIL-10 i.p. 24 h before hapten challenge on the ears. In 
each of five experiments, a statistically significant reduction in ear 
swelling compared with control animals was observed upon injec-
tion of 1000 ng or more (Fig 2A). Interestingly, there was no real 
dose-dependent effect because it was not possible to show an in-
crease of suppression by increasing the amounts of IL-I0 ir~jected. 
Optimal reduction of CHS was seen when 1000 ng was adminis-
tered 24 h before challenge (Fig 2B); injection of IL-10 less than 
12 h before challenge did not affect ear swelling. Application of 
DNFB to the ears of sensitized mice caused both epidermal and 
dermal alterations, in particular, spongiosis, edema, hemorrhage, 
and leukocyte infiltration (Fig 3A). Administration of IL-10 24 h 
before elicitation inhibited both the dermal and epidermal compo-
nent of the CHS reaction (Fig 3B). The inhibitory effect ofIL-l0 on 
the elicitation of CHS was not strain specific, because similar data 
were obtained with C3H/HeN mice (Table I). 
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Figure 2. Effect of IL-l 0 on the effector phase of CHS. IL-I0 was injected 
intraperitoneally at the concentrations indicated into ONFD-sensitized 
Balb/c mice. Twenty-four hours later challenge was performed on the left 
ear (A). IL-10 (1000 ng) was injected intraperitoneally into ONFD-sensi-
tized Dalb/c mice at the timepoints indicated before performance of ear 
challenge (B). Ear swelling was evaluated 24 h after ear challenge. CHS 
response is expressed as the difference (cm X 10- 3, mean ± SO) of the 
thickness of the challenged left ear mjnus the thickness of the vehicle-treated 
rjght ear. Ear thickness (mean ± SD) of the control was 25.7 ± 0.9 cm X 
10-3 (A) and 21.8 ± 0.9 cm X 10-3 (B). Negative controls consisted of 
unsensitized mice that were ear challenged only. Experiments were repeated 
at least three times; results show one representative experiment. • p < 0.05, 
.. P < 0.01, ••• P < 0.001 significantly different from positive control. 
To prove that the inhibition of the elicitation was indeed me-
diated by IL-l 0, a neutralizing anti - IL-l 0 antibody was used. Con-
current injection of the antibody (50.ug) blocked the IL-I0-me-
diated suppression of the effector phase of CHS. In contrast, 
application of the isotype did not affect the inhibitory activity of 
IL-I0 (data not shown). As a further control, the anti-IL-I0 anti-
body was administered in the absence oflL-l O. Although there was 
some variation in the ear thickness of challenged mice compared to 
positive control animals the differences were not statistically signif-
icant (Table I). 
To further confirm the specifity of the inhibitory effect of IL-l 0 
on the effector phase of CHS, heat-inactivated IL-I0 was used. 
Immediately prior to injection, IL-lO was heat inactivated at 90 °C 
for 30 min. The efficacy of this treatment was monitored with the 
thymocyte proliferation assay demonstrating that native IL-10 in-
duces proliferation of thymocytes in a dose-dependent manner, 
whereas heat-treated IL-l 0 did not exhibit any biologic activity (Fig 
4). Heat-inactivated IL-I0 injected intraperitoneally into sensitized 
mice 24 h before ear challenge failed to suppress the effector phase 
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Figure 3. Ear sections frol11 ONFD-sensitized mice (BaJb/ c) killed 24 h 
after application of challenging dose of ONFD. Mice were injected with 
saline (A) or with IL-10 (1000 ng) intraperitoneally. (B) 24 h before appli-
cation of the challenging dose. In A , the dermis is edematous and infiltrated 
with leukocytes. In addition, necrotic ce lls are detectable within the epider-
mis (arrow). In B, no changes are found in the epidermis and only a slight 
inflammatory infi ltrate is detectable within the dermis (hematoxylineosin; 
bar, 20 pm). 
ofCHS in Balb/c mice, in contrast to native IL-IO, which blocked it 
significantly (Table II). 
Effect of IL-l0 on Irritant Reaction To investigate whether 
IL-I0 also suppresses irritant reactions, IL-I0 was injected intra-
peritoneally into Balb/c mice 3 or 24 h before application of 1 % 
croton oil on the left ear. Toxic ear swelling, however, was not 
affected significantly in mice pretreated with IL-I0 when compared 
with control animals (treated with irritant only) (Table III). Similar 
results were obtained when benzalkonium ch loride was used as an 
irritant (Table III). 
Administration ofIL-l0 Suppresses both Induction and Eli-
citation Phase of DTH Although CHS and OTH are both 
T -cell- mediated immune reactions with delayed onset it recently 
has been shown that both reactions induced and elicited by epicu-
taneous application of hapten and injection of hapten-conjugated 
cells, respectively, are not equivalent and interchangeable [15J . 
Therefore, the effect of IL-IO on OTH induced by TNP-SC was 
studied. We first investigated whether IL-I0 has an effect on the 
induction ofOTH. For this purpose, C3H/HeN mice were injected 
intraperitoneally with 1000 ng IL-IO 24 h before sensitization by 
subcutaneous application of TNP-SC. Seven days later the mice 
were challenged by injecting TNP-SC into the footpads of sensi-
tized or control mice. In contrast to the findings with CHS, injec-
tion ofIL-IO 24 h before sensitization significantly suppressed the 
induction of OTH w hen compared with the positive controls (nor-
mal immunized animals) (Table IV showing one representative ex-
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Table I. Effect of IL-I0 on the Elicitation Phase of CHS 
Increase Ear 
Mice Sensitization' ChaJlengeb Treatment' Thieknessd % Reduction 
Balbje DNFB (0.3%) 0.4 ± 0.5 
Balbje DNFB (0.5%) DNFB (0.3%) 15.0 ± 1.8 
Balbje DNFB (0.5%) DNFB (0.3%) IL-10 4.0 ± 1.5' 
Balbje DNFB (0.5%) DNFB (0.3%) IL-10 + Ab 14.4 ± 4.4 
Balbje DNFB (0.5%) DNFB (0.3%) Ab 12.8 ± 4.8 
C3HjHeN DNFB (0.3%) 1.0 ± 1.4 
C3HjHeN DNFB (0.5%) DNFB (0.3%) 15.1 ± 1.7 
C3HjHeN DNFB (0.5%) DNFB (0.3%) IL-10 8.5 ± 4.sr 
C3HjHeN DNFB (0.5%) DNFB (0.3%) IL-tO + Ab 16.0 ± 3.3 
C3HjHeN DNFB (0.5%) DNFB (0.3%) Ab 18.5 ± 4.3 
73.3 
43.7 
• Hapten was applied on the shaved abdomen on days 1 and 2. 
I Hapten was applied on the left ear on day 6. 
' IL-IO (1000 ng) or anti-IL-IO Ab was injected intraperitoneally 24 h before performance of challenge. 
'cm X 10- 3 • 
, P < 0.00001 significantly different from positive control. 
I p < 0.01 significantly different from positive control. 
periment). The observation that IL-I0 injected intraperitoneally 
before sensitization blocks the induction of DTH, but not of CHS, 
further supports the hYfothesis that CHS and DTH are regulated by 
different pathways [15 . 
To address the effect of IL-I0 on the elicitation phase of DTH, 
IL-I0 was injected intraperitoneally 24 h before subcutaneous chal-
lenge into mice that were already sensitized by subcutaneous injec-
tion ofTNP-SC. In each of three experiments a statistically signifi-
cant reduction in footpad swelling was observed (Table IV showing 
one representative experiment). These data indicate that IL-lO is 
able to suppress the elicitation phase of CHS and DTH. However, 
IL-I0 downregulated only the induction phase of DTH, but not of 
CHS, suggesting that different mechanisms control the modulation 
of these responses. 
DISCUSSION 
A number of studies are available addressing the immunomodula-
tory effects ofIL-I0 in vitro. They provide good evidence that IL-10 
inhibits antigen presentation [3,4] and secretion of cytokines by 
macrophages [8,9]; recent data also show that IL-I0 can affect T 
cells directly [6,16]. However, only a few reports exist addressing 
the itl vivo effects of IL-l 0 in T -cell- mediated reactions. Most of 
these studies addressed the function of IL-I0 in mouse models of 
parasitic infections [17] . They have shown that IL-10 is released in 
the course of certain parasitic infections and that it suppresses mac-
rophage effector function and the release of interferon-y [18 ,19]. In 
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Figure 4. Dose-dependent growth-promoting effect of IL-10 on thymo-
eytes in the presence ofIL-2 plus IL-4. Adult thymocytes were cultured with 
serial dilutions of native murine recombinant IL-I0 (II) or heat-inactivated 
IL-I0 (6). Mean background activiry was 1302 epm. SO were within 10%. 
a recent report by Powrie et at [20], IL-I0 was shown to inhibit the 
elicitation of 48-h footpad DTH response to Leishmanial antigen in 
mice previously injected with Leishmania. Because Th 1 cells medi-
ate protective immunity in these experimental systems the data 
suggest a regulatory role of IL-l 0 in the mediation of susceptibility 
and immunity to these infections. Our own experiments aimed to 
investigate the it! vivo effects of IL-I0 in CHS, another T-cell-
mediated reaction. We expected that IL- lO will be able to block the 
induction of CHS due to the inhibitory activity on antigen presen-
tation [3,4]. However, intraperitoneal injection of murine recombi-
nant IL-IO at various concentrations did not affect the outcome of 
CHS significantly. Sensitization was not affected when IL-10 was 
applied either 24, 72, or 120 h before epicutaneous hapten applica-
tion. 
In contrast, induction of DTH could be effectively blocked by 
intraperitoneal administration of 1000 ng IL-10 24 h before sensi-
tization by subcutaneous injection of TNP-SC. Both CHS and 
DTH are T-cell-mediated immune reactions and because of many 
similarities between CHS and DTH, they previously have been 
used interchangeably [15,21-23]. Accordingly, it has been assumed 
that they are suppressed by the same mechanism following irradia-
tion with ultraviolet (UV)B light. Recently, however, major differ-
ences between these reactions became evident: although UVB-
irradiated mice could be immunized effectively for DTH by a sub-
cutaneous injection of TNP-SC derived from normal mice, this 
procedure did not restore the CHS reaction measured by painting 
TNCB of the ears [15] . Moreover, treatment of UVB-irradiated 
mice with methylprednisolone before immunization prevented the 
suppression of DTH, but had no effect on the suppression of CHS 
[15] . Thus, our findings , i.e ., that IL-10 prevents induction ofDTH 
but not of CHS, further support the hypothesis that DTH and CHS 
are based upon distinct mechanisms in which different pathways 
seem to be involved. However, we cannot exclude that by changing 
the experimental conditions, e.g., application of even higher doses, 
multiple injections, or selection of other timepoints of injection, 
IL-I0 will be able to suppress the induction of CHS ill rlivo. The 
present data, however, are in agreement with a recent observation 
by Rivas and Ulrich. Using the UVB model they could show that 
injection of an anti-IL-I0 antibody prevents UVB-induced sup-
pression of the induction of DTH [24] but not of CHS. t These data 
yield indirect evidence that IL-I0 is involved in the suppression of 
the induction of DTH, but not of CHS. Conversely, Rivas and 
Ulrich could demonstrate that application of TNF-a antibodies 
t Rivas JM, Ullrich SE: Essential role of keratinoeyte-dcrivcd interleu-
kin-IO in the UV-induced suppression of delayed type hypersensitiviry but 
not contact hypersensitiviry (abstr.)] [livest Dermatoi100:S22A, 1993. 
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Table II. Effect of IL-l 0 on the Elicitation Phase of CHS 
I ncrease car 
M ice Sensitization' C hallengeb Treatment' Thickness' % Suppression 
Balb/c DNFB (0.3%) 0.8 ± 0.8 
Balb/c DNFB (0.5%) DNFB (0.3%) 18.2 ± 5.3 
Balb/c DNFB (0. 5%) DNFB (0.3%) IL-I0 7.2 ± 4.0' 60.0 
Balb/c DNFB (0.5%) D N FB (0.3%) inactivated IL-I0 23.6 ± 4.1f 23.6 ± 4.11 
• Hapten was applied o n the razor shaved abdomen on days I and 2 . 
• Hapten was applied on the left ear on day 6. . . . 
, N ative o r inactivated IL- IO (1000 ng) was lI1Jectcd mtrapentoncally 24 h before performance of challenge. 
d cm X 10-'. 
, Significantly different from positive control (p < 0.001). 
f Nor significantly ddTerent fro m posltlve control. 
reverses UVB-induced suppression of the induction of CHS, but not 
ofDTH.·' 
Interestingly, we found that IL-10 injected intraperitoneally was 
able to suppress the elicitation of both CHS and DTH. The inhibi-
tory effect of IL-l 0 on the effector phase is speci fi c because it could 
be blocked by concurrent injection of an anti - IL-l 0 antibody. In 
several control experiments iruection of the IL-I0 antibody alone 
affected ear swelling somewhat, but these changes were never sig-
nificant. These variations may reflect neutralization of endogenous 
IL-I0. On the other hand, mice treated continuously from birth 
until 8 weeks of age with anti - IL-l 0 antibody appeared to be 
healthy and, by numerous parameters, unaffected by the treatment 
[25,26]. To furth er prove the specificity, IL-I0 was inactivated by 
heat treatment. Incubation at 90 ·C for 30 min resulted in a com-
plete loss of bioactivity, as checked in the thymocyte proliferation 
assay [14] . As expected, injection of heat-inactivated IL-I0 had no 
effect on the el icitation of CHS. 
CHS-induced ear swelling was blocked significantly by injection 
of at least 1000 ng ofIL-l O. Although lower doses had some inhibi-
tory activity, the effects were not significant. Moreover, there was 
no real dose-dependent effect because it was not possible to increase 
the inhibitory activity by increasing the amounts of IL-I0. This 
may suggest that in this complex ill vivo system probably other 
mediators are indirectly involved. To be inhibitory, IL-I0 had to be 
administered at least 12 h before hapten challenge; maximum sup-
pression was observed upon injection 24 h before challenge. The 
need of this relatively long period suggests that the observed effect 
ofIL-10 is not a direct one, but could be mediated indirectly, e.g. , via 
other cytokines. In this respect, TNF-O' appears to be of primary 
interest because it recently has been identified as a critical mediator 
in hapten-induced irritant and contact hypersensitivity reactions 
[27]. In particular, injection of anti - TNF-O' antibodies into sensi-
tized mice before application of the challenging dose of the respec-
tive hapten abrogated the ear-swelling response significantly. 
Accordingly, we recently found that pentoxifylline, a phos-
phodiesterase inhibitor known to inhibit the release of TNF-O', is 
Table III. Effect of IL-l 0 on Irritan t Reaction 
Ear Swelling' 
Treatment IL-I0 3 hb IL-1024 h' 
Croton oild 23.5 ± 2.6 23.4 ± 1.9' 20.8 ± 3.2' 
Benzalkonium 
chloridel 57.8 ± 20.7 55.4 ± 16.3' 54.5 ± 23.9' 
• Difference of th e thickness of the irritated left car minus th e thickness of the 
veh icle-treared right car (cm X 10-'). 
• IL-l 0 (1000 ng) was injected intraperitoneally 3 h before irrita nt application. 
, IL-I0 (1000 ng) was injected intraperitoncall y 24 h before irritant application. 
I 1 % croron oi l was applied on the left ear. 
, Not significant compared to positive control (irritation onl y). 
1 5% benzalkonium chl oride was applied on tlte left year. 
able to inhibit ear chall enge in sensitized mice [11]. Moreover, it 
was observed that pentoxifylline also reduces irritant dermatitis, as 
was the case by injection of anti - TNF-O' antibody, suggesting that 
TNF-O' is also of importance in the mediation of irritant reactions 
[27]. IL-lO efficiently blocks the ill Ilitro production ofTNF-O', as 
well as of other cytokines, by lipopolysaccharide-activated mono-
cytes/macrophages [8] . Through this mechanism IL-l 0 may be able 
to prevent lethality in experimental endotoxemia [13,28]. To fur-
ther elucidate w hether the inhibitory effect ofIL-I0 on the effector 
phase of CHS could be due to the inhibition of the release ofTNF-
0', the effect of IL-IO on irritant dermatitis, another TNF-O'-
mediated reaction, was studied. However, in contrast to pentoxifyl-
line and anti - TNF-O' antibody, IL-I0 was not able to reduce toxic 
ear swelling response elicited by topical application of croton oil and 
benzalkonium chloride, respectively. Although these data do not 
definitely prove it, they favor the view that inhibition of TNF-O' 
may not be the primary mechanism by which IL-IO prevents the 
effector phase of CHS. 
More likely, IL-IO may exert its inhibitory effects on CHS and 
OTH Ilia modulation of antigen-presenting cells. In a variety of 
antigen-driven secondary reactions IL-lO has been found to be in-
hibitory, acti ng primarily on antigen-presenting cells. It was shown 
that IL-I0 inhibits the ability of macrophages, but not B celis, to 
induce interferon-y secretion from Th 1 cells [3 ,4]. However, IL-I0 
has no effect on the capacity of dendritic cell s to stimulate prolifera-
tion of C04+ or C08+ T cells from unprimed mice, although 
macrophage-driven proliferation is inhibited [29], a finding in ac-
cordance with data using a mitogen-driven system [30]. The effec-
tor phase of CHS and OTH reflects a primed (secondary) i/1 "iva 
system. Therefore, the inhibitory activity ofIL-l 0 on the elicitation 
of CHS and OTH could be explained by the effects of IL-lO on 
antigen-presenting cell s, as deITlOl1strated in the ill vitro system [31] . 
On the other hand, there is recent evidence, at least in the human 
system, that IL-IO exerts direct downregulatory effects also on T 
cells [16]. In particular, it was reported that IL- 10 directly inhibits 
IL-2 production and proliferation of activated human subsets of 
C04+ T-cell clones and T cell s isolated from peripheral blood [1 6]. 
In addition, IL-IO cou ld indirectly affect either antigen-presenting 
cells or T cells by modulating the release of other cytokines, which 
could explain the relatively long period IL-I0 has to be injected to 
block CHS and DTH. Weare currently investigating whether IL-
lOin our in villo models of C HS and OTH primarily affects antigen-
presenting cells, T -effecto r cel ls, or both . 
In summary, the present study demonstrates a new ill villa func-
tion ofIL-lO, the abi lity to suppress induction ofOTH and to block 
the elicitation of both CHS and OTH. In particular, the latter find-
ings emphasize the ro le of IL-10 as an immunosuppressive and 
antiinflammatory drug, giving rise to speculation about pharmaco-
logic intervention in these types of immune reactions by application 
of IL-IO. Moreover, the observation that IL-I0 suppresses the in-
duction of OTH, but not of CHS, further supports the concept that 
OTH and CHS are related but distinct immunologic reactions in-
volving different pathways. 
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Table IV. Effect of IL-I0 on the Elicitation Phase of DTH 
Treatment Before 
Sensitization' 
IL-IO 
Sensitizationb 
SC 
TNP-SC 
TNP-SC 
TNP-SC 
TNP-SC 
Treatment Before 
Challenge' 
IL-IO 
Challenge' 
TNP-SC 
sc 
TNP-SC 
TNP-SC 
TNP-SC 
Increase Footpad 
Thickness' 
6.5 ± 1.0 
3.8 ± 1.2 
17.1 ± 1.6 
8.8 ± 1.3' 
9.8 ± 0.8' 
% Suppression 
48.3 
42.4 
• IL-IO (1000 ng) was injected intraperitoneally 24 h before sensitization and challenge, respectively. . 
b Mice were sensitized by subcutaneous injection of TNP-SC or SC (5 X 107 cells) at two sites on the dorsal skill. 
'Mice were challenged by subcutaneous injection ofTNP-SC or SC (2 X 107 cells) into the left footpad . . . . 
J Footpad swelling was measured 24 h after challenge and expressed as the difference (cm X 10- ', mean ± SO) of the tluckness of the challenged left footpad mlllusthe thIckness of 
the untreated right footpad . 
• p < 0.005 significantl y different from positive control. 
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